Tianyin Biology raises tens of millions, backed by novel NSR platform for precision psychiatry
On October 22, 2025, Shanghai Tianyin Biology Technology Co., Ltd. ("Tianyin Biology") announced the completion of a financing round exceeding tens of millions of RMB. This round was led by the Shanghai Industrial Intellectual Property Fund under Shanghai STVC Group. This milestone signifies renewed capital recognition for Tianyin Biology's proprietary technologies in the mental health sector, providing substantial momentum for its next phase of industrialization and scaled development. The raised funds will be allocated to advance technology R&D, product commercialization, market expansion, and medical insurance reimbursement processes.
Tianyin Biology is a technology spin-off from Shanghai Jiao Tong University, specializing in the objective detection and intervention of mental health disorders. The company has pioneered the world's first objective biological detection technology capable of guiding clinical interventions—the Niacin Skin Response (NSR) test. This technology enables early screening, precise assessment, and guidance for personalized treatment of depression and other mental health conditions.
Building upon this groundbreaking innovation, Tianyin Biology has established a comprehensive product portfolio covering the entire clinical pathway from "risk screening → medical testing → personalized intervention → health management":
The nation's first integrated NSR testing device registered as a Class II Innovative Medical Device.
A high-throughput NSR screening system designed for physical examinations, schools, and community settings.
The "MindGuard" portable testing bracelet and supporting intervention products for home use.
Currently, these products have been deployed for clinical application in over 30 tier-3 class-A hospitals across China. Additionally, routine testing service systems have been established in multiple universities, providing a novel, objective approach for mental health management.
Tianyin Biology's core technology, the Niacin Skin Response (NSR) test, assesses cell membrane function and enables non-invasive, objective mental health risk identification within just five minutes. This approach overcomes the limitations of traditional psychological assessments, which rely heavily on subjective questionnaires, establishing a new mental health evaluation paradigm that transitions "from perception to quantification, from subjective to objective."
To date, Tianyin Biology has:
Obtained China's first Class II Innovative Medical Device Registration Certificate for NSR technology;
Secured 25 core technology patents, with the underlying technology originating from Shanghai Jiao Tong University's Bio-X Research Institute;
Established the world's largest niacin phenotype database, comprising 50,000 clinical data records;
Developed proprietary AI deep learning image recognition algorithms to support precision diagnosis and treatment.
Driven by the triple engine of "original mechanism + clinical data + AI algorithms," Tianyin Biology is establishing a globally leading objective detection technology system for mental health disorders.
Wan Chunling, founder of Tianyin Biology and a professor at Shanghai Jiao Tong University's Bio-X Research Institute, stated: "Technological innovation is never an isolated achievement of scientific research, but rather the result of collective empowerment from industry, capital, policy, and society. Moving forward, Tianyin Biology will cherish this trust and steadfastly advance along the path from pioneering research to clinical translation, and from Chinese innovation to broader social impact. We are committed to repaying our investors with tangible results and responding to societal expectations through sustained growth, striving to become one of the most enduring innovative enterprises in the mental health field."
The completion of this funding round signifies Tianyin Biology's formal inclusion in the innovative enterprise portfolio of the Shanghai STVC Group ecosystem. It also marks another significant achievement in the mental health industry at the intersection of "medical devices + artificial intelligence + public health."
It is reported that Tianyin Biology will continue to increase its R&D investment, advance medical insurance reimbursement processes and standardization efforts, while accelerating the deployment of its products across medical institutions, physical examination centers, schools, and community settings. These efforts aim to integrate mental health screening authentically into the public health system.